Join our daily newsletter At The Bell to receive exclusive market insights
- Starpharma (SPL) relaunches its VIRALEZE nasal spray with LloydsPharmacy in the United Kingdom
- VIRALEZE will be supplied exclusively to LloydsPharmacy under its existing sales and distribution agreements
- LloydsPharmacy is one of the largest pharmacy groups in the UK and has around 1400 pharmacies in the country based predominantly in community and health centres
- VIRALEZE works by slowing down the infection of host cells when applied to cells before and after exposure to a respiratory virus
- Starpharma is up 3.73 per cent with shares trading at 70 cents at 1:23 pm AEST
Starpharma (SPL) has relaunched its VIRALEZE nasal spray with LloydsPharmacy in the United Kingdom.
VIRALEZE will be supplied exclusively to LloydsPharmacy under its existing sales and distribution agreements.
LloydsPharmacy is one of the largest pharmacy groups in the UK and has around 1400 pharmacies in the country based predominantly in community and health centres.
“We are delighted to relaunch Starpharma’s innovative nasal spray, VIRALEZE, in the UK
through LloydsPharmacy’s extensive online and retail network,” Starpharma CEO Dr Jackie Fairley said.
“VIRALEZE will be particularly useful in the winter cold and flu season given its broad spectrum of activity against multiple cold and respiratory viruses.”
VIRALEZE contains antiviral agent SPL7013 which works by slowing down the infection of host cells before and after exposure to respiratory viruses.
From there, it blocks the interaction between viral surface proteins and human cell receptor proteins.
VIRALEZE is registered in more than 30 countries and Starpharma is continuing to pursue registration and commercialisation in other countries.
Starpharma was up 3.73 per cent with shares trading at 70 cents at 1:23 pm AEST.
